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following parameters: TR/TE 14.0/5.22ms, ﬂip angle 308, 28 partitions,
partition thickness 0.5 mm, FOV 80 mm, matrix size 512512, voxel
size 0.150.15 mm, 32 averages. The total imaging time was 60 min.
Images were evaluated using a scanner software package (Syngo,
Siemens). The SC was outlined and the mean signal was calculated. A
second ROI was placed outside the animal contours for noise
measurement. The mean signal-to-noise ratio (SNR) and standard
deviation (SD) were calculated.
Results: After 2–3 days, a homogeneous enhancement in the SC lasting
for 36 h was observed, after which a slow washout started. Uninjured
animals displayed a homogeneous SNR of about 18without and 36with
contrast agent throughout the SC. Proximal to the injury, injured mice
showed an SNRcomparable to uninjuredmice. Onmoving further distal
towards the lesion, the SNR gradualy decreased, reaching background
levels just at the lesion site.
Conclusion: An in vivo method for structural and functional spinal
cord imaging in mice using MEMRI was developed. Manganese was
readily taken up and transported through the spinal cord althoughmeans
of uptake and transportation need to be elucidated. Changes in
manganese uptake proﬁles on comparing injured and healthy mice
suggest a function-dependent decrease in uptake in the injured mice.
The decrease in enhancement proximal to the lesion site may correlate
with dying back of axons. The decrease to baseline levelsmay indicate a
near total loss of functional neurons at these levels. Correlation with
histology supports this hypothesis.
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Rationale and Objectives: A ﬁrst clinical trial of orally administered
manganese with and without ascorbic acid as a promoting agent in liver
MRI was planned. The objectives of the study were to assess efﬁcacy of
the contrast agent in doses up to 100 mmol/kg bw, assess whether
addition of ascorbic acid (molar ratio 1:2) to the contrast agent improved
enhancements in the liver to such a degree that it may be of clinical
importance and to assess acute safety.
Methods: Eighteen healthy adult males were enrolled in the trial. The
mean age was 25.0 years and mean weight 77.6 kg. Contrast medium:
drug: MnCl2 doses were 25, 50 and 100 mmol/kg bw, respectively and
promoting agent: ascorbic acid doseswere 50, 100 and 200mmol/kg bw,
respectively. The trial was designed as a phase I, cross-over trial with
two study periods separated by a wash-out period of 4 weeks.
All imaging was performed on a 1.5 T clinical MRI system (Siemens
Somatom Vision, Erlangen, Germany). Three pulse sequences in the
abdomen were used: (i) T1-weighted axial gradient-echo (GE), TR/TE
52.5/4.8 ms, ﬂip angle 808, thickness 10.0 mm and scan time 20 s; (ii) as
for (i) but in the coronal plane; and (iii) T1-weighted axial spin-echo
(SE), TR/TE 250/12 ms, fat suppression, thickness 10.0 mm, averages 7
and scan time 5 min 39 s. To gather information about contrast passage
from ventricle to small intestine, occasionally more pulse sequences
were used in the coronal plane, but no quantitative analysis was
performed of the bowel distribution of the contrast agent. Phantom vials
containing standardized Ni–agarose gels were placed in a ﬁxed position
under the patient in the bed and used for signal intensity measurements.
Time points for imagingwere precontrast and 1, 2.5, 4, 6, 9 and 24 h after
MnCl2 intake. Safety parameters assessed in the trial were clinical
examinations and vital signs including heart rate and blood pressure.
Hematology and clinical chemistry were assessed with standard
laboratory procedures.
Results: All pulse sequences showed a clear dose–response in the liver.
High enhancements in the liver were seen between 2.5 and 6 h after
MnCl2 intake. At a manganese dose of 50 mmol/kg bw with ascorbic
acid and at a dose 100mmol/kg bw both without and with ascorbic acid,
the hepatic enhancements were higher than 100%, GE pulse sequence.
Using the volunteers as their own controls, the promoting effect of
ascorbic acid was signiﬁcant at a manganese dose of 100 mmol/kg bw.
The contrast agent distributed well in the small intestine, delineating
intra-abdominal organs well. No serious or unexpected adverse events
were encountered. The drug was generally tolerated well except for
gastrointestinal adverse events such as loose stool (n¼ 12), nausea (6)
and vomiting (1). No signiﬁcant alteration in hematology or clinical
chemistry was seen.
Conclusion: Oral manganese is easy to use and has few side-effects.
Besides the liver-speciﬁc effect, the agent delineates the intestine.
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Rationale andObjectives: Recently, a new liver speciﬁcMRagent has
been introduced that is administered orally and only small amounts enter
the general circulation. It is the only contrast medium that is delivered to
the liver in high doses in the portal vein and very low doses in the hepatic
artery. It is taken up by the hepatocytes and excreted together by the bile.
We recently received permission from the Danish Health Authorities to
use CMC-001 clinically (phase IV). In this paper we evaluate
retrospectively our preliminary experience.
Methods: Six patients were studied. All had known liver metastases
from colorectal cancers. Frommidnight the patients were not allowed to
drink or eat. Between 8 and 9 a.m. the patients drank CMC-001
dissolved in 400 mL of water and 2 h later the MR examination (1.5 T)
took place. The sequences are still being optimized.
Results: In three of the six patients, important new knowledge was
obtained. The uptake in the liverwas excellent in all patients. Therewere
segmental differences in the uptake in four of the six patients, probably
due to early ﬁbrosis induced by chemotherapeutics or decreased portal
vein ﬂow due to metastatic compression. There was excellent
visualization of the biliary system on the T1-weighed images. No
contrast medium adverse events were reported.
Conclusion: CMC-001 seems to be useful in the work-up of patients
with liver metastases regarding both the liver parenchyma and the
biliary tract. Further research is strongly warranted.
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